Revenue growth remains highly erratic, exemplified by a 451.8% spike in 2025Q1 followed by inconsistent performance that underscores a lack of scalable operational maturity.
| Sales/Revenue | 18.37M | 16.37M | 4.05M | 145.29K | 511K | 120K | 63K |
| Revenue Growth % | 154.57% | 303.98% | 2688.61% | -71.57% | 325.83% | 90.48% | - |
| Cost of Goods Sold | 8.96M | 8.33M | 2.48M | 132.43K | 344K | 0 | 0 |
| COGS % of Revenue | - | 50.88% | 61.32% | 91.15% | 67.32% | - | - |
| Gross Profit | 9.41M | 8.04M | 1.57M | 12.86K | 167K | 120K | 63K |
| Gross Margin % | 51.22% | 49.12% | 38.68% | 8.85% | 32.68% | 100% | 100% |
| Gross Profit Growth % | - | 412.94% | 12084.09% | -92.3% | 39.17% | 90.48% | - |
| Operating Expenses | 18.47M | 18.37M | 9.33M | 22.2M | 40.33M | 15.15M | 8.79M |
| OpEx % of Revenue | - | 112.22% | 230.26% | 15280.01% | 7893.15% | 12625.83% | 13957.14% |
| Selling, General & Admin | 11.47M | 11.36M | 7.17M | 19.4M | 25.83M | 10.27M | 6.89M |
| SG&A % of Revenue | - | 69.4% | 176.94% | 13352.24% | 5054.01% | 8560% | 10944.44% |
| Research & Development | 188.05K | 182.5K | 312.27K | 900.43K | 3.05M | 4.88M | 1.9M |
| R&D % of Revenue | - | 1.11% | 7.71% | 619.74% | 596.28% | 4065.83% | 3012.7% |
| Other Operating Expenses | 808.07K | 6.83M | 1.85M | 1.9M | 11.46M | 0 | 0 |
| Operating Income | -9.06M | -10.33M | -7.76M | -22.19M | -40.17M | -15.03M | -8.73M |
| Operating Margin % | -49.33% | -63.11% | -191.58% | -15271.16% | -7860.47% | -12525.83% | -13857.14% |
| Operating Income Growth % | - | -33.08% | 65.02% | 44.76% | -167.23% | -72.18% | - |
| EBITDA | -8.58M | -9.73M | -6.53M | -20.91M | -38.65M | -14.93M | -7.46M |
| EBITDA Margin % | -46.7% | -59.46% | -161.09% | -14390.92% | -7563.99% | -12444.17% | -11849.21% |
| EBITDA Growth % | -22.32% | -49.1% | 68.78% | 45.91% | -158.84% | -100.04% | - |
| D&A (Non-Cash Add-back) | 482.44K | 597.43K | 1.24M | 1.28M | 1.51M | 98K | 1.26M |
| EBIT | -9.95M | -9.2M | -8.51M | -25.39M | -93.81M | -37.37M | -8.73M |
| Net Interest Income | -3.52M | -3.43M | -3.91M | -1.06M | -1.44M | -1.12M | 61K |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 61K |
| Interest Expense | 368.6K | -3.43M | 3.91M | 1.06M | 1.44M | 1.12M | 0 |
| Other Income/Expense | -4.41M | -2.3M | -4.66M | -4.26M | -55.09M | -23.46M | 77K |
| Pretax Income | -13.46M | -12.63M | -12.42M | -26.45M | -95.25M | -38.49M | -8.65M |
| Pretax Margin % | -73.31% | -77.16% | -306.57% | -18205.21% | -18640.9% | -32073.33% | -13734.92% |
| Income Tax | -194.15K | -199.57K | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 1.44% | 1.58% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -13.27M | -12.43M | -12.41M | -26.45M | -95.25M | -38.49M | -8.65M |
| Net Margin % | -72.23% | -75.94% | -306.21% | -18205.21% | -18640.9% | -32073.33% | -13734.92% |
| Net Income Growth % | -15.17% | -0.19% | 53.1% | 72.23% | -147.49% | -344.79% | - |
| Net Income (Continuing) | -13.26M | -12.43M | -12.42M | -26.45M | -95.25M | -38.49M | -8.65M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | -71.89K | -68.68K | -51.94K | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.00 | -0.13 | -0.93 | -7.08 | -84.00 | -66.13 | -43.27 |
| EPS Growth % | -3.01% | 86.02% | 86.86% | 91.58% | -27.02% | -52.85% | - |
| EPS (Basic) | - | -0.13 | -0.93 | -7.08 | -84.00 | -66.13 | -43.27 |
| Diluted Shares Outstanding | 3.11B | 264.78M | 14.61M | 4.22M | 1.13M | 582K | 200K |
| Basic Shares Outstanding | 3.11B | 264.78M | 13.37M | 3.74M | 1.13M | 582K | 200K |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
Imminent liquidity crisis
As reported in recent quarterly filings, FOXO experienced significant revenue fluctuations, including a 451.8% growth spike in 2025Q1 followed by subsequent variability, suggesting that the company's top-line expansion remains highly sensitive to pilot program timing rather than a consistent, recurring commercial adoption of its epigenetic testing services.
The erratic nature of revenue growth indicates that the firm has yet to establish a predictable sales pipeline or recurring revenue model. Investors should monitor whether these swings represent genuine market penetration or merely the lumpy recognition of one-time insurance carrier integration fees.
Based on the provided financial data, gross margins have oscillated wildly from a low of -10.7% in 2024Q2 to a peak of 100% in 2024Q1, highlighting a lack of operational maturity and the difficulty in scaling the underlying laboratory processing costs against fluctuating service volumes.
The inability to maintain a stable gross margin suggests that the company's cost of revenue is not yet optimized for volume. This volatility implies that the firm lacks the pricing power or cost control necessary to support its high-fixed-cost operating structure.
According to the income statement history, FOXO's operating expenses consistently dwarf gross profits, resulting in an operating margin of -63.11% and suggesting that the company has failed to achieve the necessary scale to leverage its bioinformatics and actuarial personnel costs effectively against current revenue levels.
The persistent gap between gross profit and operating expenses indicates that the business model is currently unable to cover its overhead. Without a significant shift toward automated licensing or a massive increase in throughput, the current operating structure appears fundamentally unsustainable.
With cash and equivalents reported at approximately $207,453, the company faces an acute liquidity risk that, as indicated by historical financial statements, may necessitate immediate dilutive financing to maintain operations, casting doubt on the firm's ability to continue as a going concern in the near term.
The extreme depletion of cash reserves relative to quarterly burn rates suggests that the company is operating on a razor-thin margin of safety. Market participants should be wary of the high probability of equity dilution, which could significantly impair shareholder value regardless of any potential long-term technological promise.
Quick answers to the most common questions about buying FOXO stock.
For fiscal year 2025, FOXO Technologies Inc. (FOXO) reported total revenue of $16.4M. This represents a 25880.3% increase compared to $0.1M in 2020.
FOXO Technologies Inc. (FOXO) reported a net loss of $12.4M for the fiscal year ending 2025.
FOXO Technologies Inc. (FOXO) reported an operating income of $-10.3M, resulting in an operating profit margin of -63.1%. This margin reflects the operational efficiency of the business before interest and taxes.
FOXO Technologies Inc. (FOXO) generated $8.0M in gross profit for the year, representing a gross profit margin of 49.1%. This demonstrates the company's core pricing power and production efficiency.